DOHA: Weill Cornell Medical College in Qatar (WCMC-Q) and SomaLogic announced that the automated version of SOMAscan assay, previously available at SomaLogic’s headquarters in Boulder, CO, will be installed at WCMC-Q campus in Education City.
In addition to being the first automated site outside SomaLogic, it is also the first placement of assay outside North America.
“The assay is a key component of the cutting-edge biomedical technology provided in Qatar by Weill Cornell Medical College,” said Dr Johannes Graumann, Assistant Professor of Biochemistry and Director of Proteomics Core, WCMC-Q.
“It will help us achieve our mission to support and foster cross-institutional collaboration, improve our understanding of disease mechanisms, identify markers of disease and progression and improve patient care.”
Compared to other proteomic technologies, SomaLogic provides researchers with power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.
SOMAmer (Slow Off-rate Modified Aptamer) reagents, at the centre of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of monoclonal antibodies and traditional aptamers.
The Peninsula
